Morning Pitch Asia Bio Tech @Korea
Description
We are back with HYBRYD edition of Morning Pitch, on 16th May, where we feature startups working in Bio Tech space. In this session we are going to host both in-person and online style Morning Pitch Asia!
Morning Pitch is the pitching platform hosted by Deloitte where we aim to create collaborations between large corporations/investors and startups.
The event series was originally launched in Japan in 2013, where it has been organized over 450 times, over 2,000 startups have pitched, and more than 60 IPOs and 250 business alliances have been created.
Venue:
In-person*: The Forum, Room#303, 3rd Fl. Two IFC, 10, Gukjegeumyung-ro, Youngdeungo-gu, Seoul, 07329, Korea MAP
Online: Zoom Webinar
*Due to limitation of capacity on the venue, it would be first-come-first-served basis.
Pitching startups:
Mireaecellbio – Mirae Cell Bio is a next-generation cell therapy development company. We are developing MSC (Mesenchymal Stem Cell) cell therapy using ENS (Epithelial-mesenchymal transition based Natural Selection) platform technology. We also possess a GMP certified medical therapy manufacturing facility used for the production of cell therapy agents. Our phase 2 drug candidate, designated as an orphan drug in Korea, is the first-in-class drug targeting interstitial cystitis.
*MSC: Also known as Multipotent stromal cells that can differentiate into a variety of cell types
*ENS: By recreating human development in vitro without chemical treatment, differentiation is induced by natural selection without cell damage.
URL: http://www.miraecellbio.com/
Neuracle Science – Neuracle Science is a clinical-stage biotech company focused on discovering and developing novel antibody therapeutics for the treatment of neurological disorders. Our lead antibody program is NS101, which provides a promising therapeutic option to treat multiple neurological diseases caused by synapse loss. We have completed a phase 1 trial for NS101 and expect to start a phase 2 trial in Korea in 2H of 2023.
URL: http://www.neuracles.com/
LISCure Biosciences – LISCure Biosciences is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the therapeutic areas where high unmet medical needs exist. LISCure Biosciences creates the "Next Generation Microbial Therapeutics" utilizing our own screening platform technology based on a proprietary in-house microorganism bank. Our phase 2 drug candidate has been designated as an orphan drug by the US FDA in 2022.
URL: https://www.liscure.bio/
ImmunAbs – ImmunAbs is a clinical-stage biotech company established by experts in global standard antibody therapeutics development. ImmunAbs has 20 years of experience in developing best-in-class monoclonal antibodies using technologies such as phage display and single B cell cloning to obtain humanized antibodies from immunized animal species. Our lead pipeline is currently in a phase 1 clinical trial in the US and will move forward to a phase 2a clinical trial in 2024.
URL: http://www.immunabs.com/
Privacy Notice
Deloitte is a privacy conscious global organization. We will treat the information we collect from you as a result of your registration and participation for this event in accordance with our Privacy Policy, which is located at
https://www2.deloitte.com/jp/ja/legal/privacy.html
https://www2.deloitte.com/kr/en/legal/privacy.html
Time
May 16, 2023 9:30 AM Seoul